Unboosted twice-daily atazanavir plus raltegravir
26 August 2010. Related: Conference reports, Antiretrovirals.
Antiretrovirals
CASCADE analysis of when to start treatment
26 August 2010. Related: Conference reports, Antiretrovirals.
Impact of antiretroviral PMTCT prophylaxis regimens on subsequent maternal disease progression in Kesho Bora
26 August 2010. Related: Conference reports, Antiretrovirals, Pregnancy.
Birth outcomes with antiretroviral exposure
26 August 2010. Related: Conference reports, Antiretrovirals, Pregnancy.
No difference in outcomes for children initiating treatment with a protease inhibitor or an NNRTI nor with viral load switching strategies in PENPACT-1
26 August 2010. Related: Conference reports, Antiretrovirals, Paediatric care.
Tablets more acceptable than syrups in the ARROW trial
26 August 2010. Related: Conference reports, Antiretrovirals, Treatment strategies, Paediatric care.
Paediatric formulation of TMC 278
26 August 2010. Related: Conference reports, Antiretrovirals, Paediatric care.
FDA safety updates to antiretroviral labels
26 August 2010. Related: Antiretrovirals.
Raltegravir approved inScotland
26 August 2010. Related: Antiretrovirals, Treatment access.
Atazanavir/r approved in Europefor children aged 6 to 18 years
26 August 2010. Related: Antiretrovirals, Treatment access, Paediatric care.
FDA finally approves 4th generation HIV Ag/Ab test in the US
26 August 2010. Related: Antiretrovirals, Treatment access, Pregnancy, Paediatric care, Diagnostics.
Antiretroviral pipeline 2010
1 July 2010. Related: Pipeline report, Antiretrovirals.
HIV diagnostics pipeline
1 July 2010. Related: Pipeline report, Antiretrovirals, Diagnostics.
START study launched and endorsed by broad community support: over 140 community organisations sign letter to US guideline panel
1 June 2010. Related: Antiretrovirals.
FDA safety updates to antiretroviral labels
1 June 2010. Related: Antiretrovirals.
Development of apricitabine halted without finding backer for Phase 3
1 June 2010. Related: Antiretrovirals.
Treatment reduces infections by over 90%: a theme that is here to stay
2 April 2010. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
ACTG 5205: atazanavir/ritonavir vs efavirenz in treatment naive patients
2 April 2010. Related: Conference reports, Antiretrovirals, Side effects, Weight, diabetes, metabolic complications.
Pipeline compounds and new approaches to treatment
2 April 2010. Related: Conference reports, Antiretrovirals.
Non-refrigerated ritonavir tablet approved in Europe and the US
2 April 2010. Related: Antiretrovirals.
FDA safety review of saquinavir (Invirase) and possible association with abnormal heart rhythms
2 April 2010. Related: Antiretrovirals.
FDA updates US label for darunavir (Prezista)
2 April 2010. Related: Antiretrovirals.
FDA safety announcement about ddI and non-cirrhotic portal hypertension
2 April 2010. Related: Antiretrovirals.
FDA label change for lopinavir/r (Kaletra)
2 April 2010. Related: Antiretrovirals.
FDA notice about drug interactions with etravirine (Intelence)
2 April 2010. Related: Antiretrovirals.
Once-daily darunavir/r monotherapy is suboptimal as initial regimen in treatment-naive people
21 February 2010. Related: Conference reports, Antiretrovirals.
GSK issues Dear Doctor letter in the US: fosamprenavir and cardiovascular risk
16 February 2010. Related: Antiretrovirals, Side effects.
Recent ARVs and the blood/brain barrier: CSF drug concentrations of darunavir/r and raltegravir
31 December 2009. Related: Conference reports, Antiretrovirals.
Tibotec issues Dear Doctor letter in Europe concerning severe etravirine reactions: three case reports
30 December 2009. Related: Treatment alerts, Antiretrovirals.
GSK and Pfizer launch joint HIV collaboration
30 December 2009. Related: Antiretrovirals.
First results of new integrase compound: GSK1349572
5 October 2009. Related: Conference reports, Antiretrovirals.
Raltegravir in treatment-naive patients
5 October 2009. Related: Conference reports, Antiretrovirals.
Nevirapine vs atazanavir/ritonavir in treatment-naive patients: ARTEN study
5 October 2009. Related: Conference reports, Antiretrovirals.
Darunavir/r monotherapy studies
5 October 2009. Related: Conference reports, Antiretrovirals.
Maraviroc results similar to efavirenz when analysed using more sensitive tropism test
5 October 2009. Related: Conference reports, Antiretrovirals.
Maximal suppression achieved with three drugs: no additional virological impact of raltegravir intensification
5 October 2009. Related: Conference reports, Antiretrovirals.
CD4 responses after viral suppression for more than 7 years on HAART
5 October 2009. Related: Antiretrovirals.
Raltegravir approved in Europe for treatment-naive patients
5 October 2009. Related: Antiretrovirals.
50mg and 100mg ritonavir doses achieve similar levels of saquinavir in Thai patients
5 October 2009. Related: Antiretrovirals.
Etravirine (Intelence) label change in the US due to severe hypersensitivity reactions
2 October 2009. Related: Antiretrovirals.
Four weeks lopinavir/r to cover functional monotherapy when stopping HAART
23 August 2009. Related: Conference reports, Antiretrovirals.
Efavirenz-related studies: genetics, smoking and TDM
23 August 2009. Related: Conference reports, Antiretrovirals.
Atazanavir: a suitable case for TDM?
23 August 2009. Related: Conference reports, Antiretrovirals.
Raltegravir approved in the US for treatment-naive patients: paranoia and anxiety added as side effects
22 August 2009. Related: Antiretrovirals.
EMEA positive opinion on using tipranavir and darunavir in younger patients
3 June 2009. Related: Antiretrovirals.
Lopinavir/r (Kaletra) cardiovascular risk requires FDA label changes
3 June 2009. Related: Antiretrovirals.
NEJM paper: NA-ACCORD cohort study on when to start treatment
3 June 2009. Related: Antiretrovirals.
NA ACCORD results support the importance of the START study: response to researchers
3 June 2009. Related: Antiretrovirals.
EMEA statement on abacavir and the risk of heart attack
3 June 2009. Related: Antiretrovirals.
Increased atazanavir dose recommended when used in combination with efavirenz or Atripla in naive patients
19 February 2009. Related: Antiretrovirals.
Summary of antiretroviral studies at Glasgow
18 February 2009. Related: Conference reports, Antiretrovirals.
EMEA approves once-daily darunavir/ritonavir (800mg/100mg) for treatment-naive patients in Europe
10 February 2009. Related: Antiretrovirals.
Maraviroc safety label changes included with US traditional approval
9 February 2009. Related: Antiretrovirals.
US approval of paediatric abacavir
9 February 2009. Related: Antiretrovirals.
EMEA supports extension of D:A:D study until at least 2012 and the new remit to include non-AIDS cancers and kidney disease
9 February 2009. Related: Antiretrovirals, Cancer and HIV.
Applications to approve non-refrigerated ritonavir submitted to EMEA and FDA
9 February 2009. Related: Antiretrovirals.
Studies of pipeline drugs: RDEA806, PRO140, bevirimat, elvucitabine
26 December 2008. Related: Conference reports, Antiretrovirals.
Other antiretroviral studies at ICAAC
26 December 2008. Related: Conference reports, Antiretrovirals.
Non alcoholic fatty liver disease (NAFLD) is common among HIV-positive patients
26 December 2008. Related: Conference reports, Antiretrovirals.
FDA approves new paediatric AZT dosing
26 December 2008. Related: Antiretrovirals.
US revisions to darunavir label include once-daily indication for naive patients
26 December 2008. Related: Antiretrovirals.
Baseline renal insufficiency and mortality risk in HIV-positive adults in Zambia
26 December 2008. Related: Antiretrovirals.
Inflammatory and coagulation biomarkers linked to mortality in large treatment interruption trial
26 December 2008. Related: Antiretrovirals.
Abacavir and heart disease: SMART study supports an abacavir-associated increased risk of cardiovascular disease
30 October 2008. Related: Conference reports, Antiretrovirals, Side effects.
EMEA state that animal studies support no increased risk of malignancy from contamination of nelfinavir (Viracept) with ethyl mesilate (EMS)
30 October 2008. Related: Antiretrovirals, Side effects.